QIAGEN N.V. (QGEN) Stock Fundamental Analysis
USA - New York Stock Exchange - NYSE:QGEN - NL0015002CX3 - Common Stock
48.29 USD
-0.16 (-0.33%)
48.29 USD
0 (0%)
QGEN gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 57 industry peers in the Life Sciences Tools & Services industry. QGEN scores excellent points on both the profitability and health parts. This is a solid base for a good stock. QGEN has a decent growth rate and is not valued too expensively. These ratings would make QGEN suitable for quality investing!
1. Profitability
1.1 Basic Checks
QGEN had positive earnings in the past year.
In the past year QGEN had a positive cash flow from operations.
Each year in the past 5 years QGEN has been profitable.
Each year in the past 5 years QGEN had a positive operating cash flow.
1.2 Ratios
The Return On Assets of QGEN (6.19%) is better than 82.46% of its industry peers.
Looking at the Return On Equity, with a value of 11.11%, QGEN belongs to the top of the industry, outperforming 82.46% of the companies in the same industry.
QGEN's Return On Invested Capital of 7.44% is fine compared to the rest of the industry. QGEN outperforms 78.95% of its industry peers.
The Average Return On Invested Capital over the past 3 years for QGEN is significantly below the industry average of 14.00%.
The last Return On Invested Capital (7.44%) for QGEN is above the 3 year average (7.25%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.19% | ||
| ROE | 11.11% | ||
| ROIC | 7.44% |
ROA(3y)4.59%
ROA(5y)5.65%
ROE(3y)7.84%
ROE(5y)10.58%
ROIC(3y)7.25%
ROIC(5y)7.96%
1.3 Margins
QGEN's Profit Margin of 19.58% is amongst the best of the industry. QGEN outperforms 94.74% of its industry peers.
In the last couple of years the Profit Margin of QGEN has declined.
With an excellent Operating Margin value of 27.02%, QGEN belongs to the best of the industry, outperforming 96.49% of the companies in the same industry.
In the last couple of years the Operating Margin of QGEN has grown nicely.
QGEN has a Gross Margin of 64.10%. This is amongst the best in the industry. QGEN outperforms 85.96% of its industry peers.
QGEN's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 27.02% | ||
| PM (TTM) | 19.58% | ||
| GM | 64.1% |
OM growth 3Y-5.04%
OM growth 5Y4.09%
PM growth 3Y-42.96%
PM growth 5YN/A
GM growth 3Y-0.32%
GM growth 5Y-0.63%
2. Health
2.1 Basic Checks
QGEN has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
Compared to 1 year ago, QGEN has less shares outstanding
QGEN has less shares outstanding than it did 5 years ago.
QGEN has a better debt/assets ratio than last year.
2.2 Solvency
QGEN has an Altman-Z score of 3.62. This indicates that QGEN is financially healthy and has little risk of bankruptcy at the moment.
QGEN's Altman-Z score of 3.62 is fine compared to the rest of the industry. QGEN outperforms 68.42% of its industry peers.
The Debt to FCF ratio of QGEN is 4.50, which is a neutral value as it means it would take QGEN, 4.50 years of fcf income to pay off all of its debts.
QGEN has a better Debt to FCF ratio (4.50) than 73.68% of its industry peers.
QGEN has a Debt/Equity ratio of 0.45. This is a healthy value indicating a solid balance between debt and equity.
QGEN has a Debt to Equity ratio of 0.45. This is in the lower half of the industry: QGEN underperforms 63.16% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.45 | ||
| Debt/FCF | 4.5 | ||
| Altman-Z | 3.62 |
ROIC/WACC0.88
WACC8.42%
2.3 Liquidity
QGEN has a Current Ratio of 2.60. This indicates that QGEN is financially healthy and has no problem in meeting its short term obligations.
QGEN's Current ratio of 2.60 is in line compared to the rest of the industry. QGEN outperforms 47.37% of its industry peers.
A Quick Ratio of 2.30 indicates that QGEN has no problem at all paying its short term obligations.
QGEN has a Quick ratio (2.30) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.6 | ||
| Quick Ratio | 2.3 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 8.18% over the past year.
QGEN shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 7.92% yearly.
The Revenue has been growing slightly by 5.32% in the past year.
QGEN shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 5.32% yearly.
EPS 1Y (TTM)8.18%
EPS 3Y-7.35%
EPS 5Y7.92%
EPS Q2Q%4.04%
Revenue 1Y (TTM)5.32%
Revenue growth 3Y-4.22%
Revenue growth 5Y5.32%
Sales Q2Q%6.09%
3.2 Future
Based on estimates for the next years, QGEN will show a quite strong growth in Earnings Per Share. The EPS will grow by 9.41% on average per year.
Based on estimates for the next years, QGEN will show a small growth in Revenue. The Revenue will grow by 7.12% on average per year.
EPS Next Y7.77%
EPS Next 2Y7.68%
EPS Next 3Y8.33%
EPS Next 5Y9.41%
Revenue Next Year4.96%
Revenue Next 2Y5.54%
Revenue Next 3Y5.79%
Revenue Next 5Y7.12%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 20.38, which indicates a rather expensive current valuation of QGEN.
Based on the Price/Earnings ratio, QGEN is valued cheaper than 91.23% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 27.19. QGEN is valued slightly cheaper when compared to this.
A Price/Forward Earnings ratio of 18.63 indicates a rather expensive valuation of QGEN.
92.98% of the companies in the same industry are more expensive than QGEN, based on the Price/Forward Earnings ratio.
When comparing the Price/Forward Earnings ratio of QGEN to the average of the S&P500 Index (23.88), we can say QGEN is valued slightly cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20.38 | ||
| Fwd PE | 18.63 |
4.2 Price Multiples
91.23% of the companies in the same industry are more expensive than QGEN, based on the Enterprise Value to EBITDA ratio.
QGEN's Price/Free Cash Flow ratio is rather cheap when compared to the industry. QGEN is cheaper than 87.72% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 22.16 | ||
| EV/EBITDA | 14.16 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
QGEN has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)2.62
PEG (5Y)2.57
EPS Next 2Y7.68%
EPS Next 3Y8.33%
5. Dividend
5.1 Amount
With a yearly dividend of 0.56%, QGEN is not a good candidate for dividend investing.
QGEN's Dividend Yield is rather good when compared to the industry average which is at 0.09. QGEN pays more dividend than 94.74% of the companies in the same industry.
With a Dividend Yield of 0.56, QGEN pays less dividend than the S&P500 average, which is at 1.94.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.56% |
5.2 History
QGEN is new to the dividend game and has less than 3 years of track record.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
DPN/A
EPS Next 2Y7.68%
EPS Next 3Y8.33%
48.29
-0.16 (-0.33%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners85.46%
Inst Owner Change0%
Ins Owners0.44%
Ins Owner ChangeN/A
Market Cap10.47B
Revenue(TTM)2.07B
Net Income(TTM)405.37M
Analysts74.17
Price Target51.47 (6.59%)
Short Float %3.17%
Short Ratio5.75
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.56% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.14%
Min EPS beat(2)-2.4%
Max EPS beat(2)2.11%
EPS beat(4)2
Avg EPS beat(4)0.92%
Min EPS beat(4)-3.85%
Max EPS beat(4)7.8%
EPS beat(8)5
Avg EPS beat(8)1.59%
EPS beat(12)8
Avg EPS beat(12)2.59%
EPS beat(16)12
Avg EPS beat(16)5.18%
Revenue beat(2)0
Avg Revenue beat(2)-0.42%
Min Revenue beat(2)-0.72%
Max Revenue beat(2)-0.12%
Revenue beat(4)1
Avg Revenue beat(4)-0.33%
Min Revenue beat(4)-1.92%
Max Revenue beat(4)1.43%
Revenue beat(8)1
Avg Revenue beat(8)-0.6%
Revenue beat(12)2
Avg Revenue beat(12)-0.64%
Revenue beat(16)6
Avg Revenue beat(16)0.46%
PT rev (1m)-0.39%
PT rev (3m)-1.76%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-1.96%
EPS NY rev (1m)-0.77%
EPS NY rev (3m)-0.19%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-1.91%
Revenue NY rev (1m)-0.05%
Revenue NY rev (3m)-0.28%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20.38 | ||
| Fwd PE | 18.63 | ||
| P/S | 5.06 | ||
| P/FCF | 22.16 | ||
| P/OCF | 15.92 | ||
| P/B | 2.87 | ||
| P/tB | 13.13 | ||
| EV/EBITDA | 14.16 |
EPS(TTM)2.37
EY4.91%
EPS(NY)2.59
Fwd EY5.37%
FCF(TTM)2.18
FCFY4.51%
OCF(TTM)3.03
OCFY6.28%
SpS9.55
BVpS16.83
TBVpS3.68
PEG (NY)2.62
PEG (5Y)2.57
Graham Number29.96
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.19% | ||
| ROE | 11.11% | ||
| ROCE | 10.03% | ||
| ROIC | 7.44% | ||
| ROICexc | 10.67% | ||
| ROICexgc | 39.98% | ||
| OM | 27.02% | ||
| PM (TTM) | 19.58% | ||
| GM | 64.1% | ||
| FCFM | 22.82% |
ROA(3y)4.59%
ROA(5y)5.65%
ROE(3y)7.84%
ROE(5y)10.58%
ROIC(3y)7.25%
ROIC(5y)7.96%
ROICexc(3y)9.42%
ROICexc(5y)10.13%
ROICexgc(3y)34.6%
ROICexgc(5y)42.77%
ROCE(3y)9.77%
ROCE(5y)10.73%
ROICexgc growth 3Y-31.24%
ROICexgc growth 5Y-2.41%
ROICexc growth 3Y-13.09%
ROICexc growth 5Y6.48%
OM growth 3Y-5.04%
OM growth 5Y4.09%
PM growth 3Y-42.96%
PM growth 5YN/A
GM growth 3Y-0.32%
GM growth 5Y-0.63%
F-Score8
Asset Turnover0.32
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.45 | ||
| Debt/FCF | 4.5 | ||
| Debt/EBITDA | 2.17 | ||
| Cap/Depr | 97.52% | ||
| Cap/Sales | 8.94% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 87.76% | ||
| Profit Quality | 116.56% | ||
| Current Ratio | 2.6 | ||
| Quick Ratio | 2.3 | ||
| Altman-Z | 3.62 |
F-Score8
WACC8.42%
ROIC/WACC0.88
Cap/Depr(3y)78.4%
Cap/Depr(5y)95.94%
Cap/Sales(3y)7.97%
Cap/Sales(5y)9.87%
Profit Quality(3y)273.85%
Profit Quality(5y)189.74%
High Growth Momentum
Growth
EPS 1Y (TTM)8.18%
EPS 3Y-7.35%
EPS 5Y7.92%
EPS Q2Q%4.04%
EPS Next Y7.77%
EPS Next 2Y7.68%
EPS Next 3Y8.33%
EPS Next 5Y9.41%
Revenue 1Y (TTM)5.32%
Revenue growth 3Y-4.22%
Revenue growth 5Y5.32%
Sales Q2Q%6.09%
Revenue Next Year4.96%
Revenue Next 2Y5.54%
Revenue Next 3Y5.79%
Revenue Next 5Y7.12%
EBIT growth 1Y18.55%
EBIT growth 3Y-9.05%
EBIT growth 5Y9.63%
EBIT Next Year57.21%
EBIT Next 3Y22.16%
EBIT Next 5Y15.78%
FCF growth 1Y71.67%
FCF growth 3Y5.12%
FCF growth 5Y55.1%
OCF growth 1Y52.1%
OCF growth 3Y1.77%
OCF growth 5Y15.28%
QIAGEN N.V. / QGEN FAQ
Can you provide the ChartMill fundamental rating for QIAGEN N.V.?
ChartMill assigns a fundamental rating of 6 / 10 to QGEN.
Can you provide the valuation status for QIAGEN N.V.?
ChartMill assigns a valuation rating of 6 / 10 to QIAGEN N.V. (QGEN). This can be considered as Fairly Valued.
What is the profitability of QGEN stock?
QIAGEN N.V. (QGEN) has a profitability rating of 8 / 10.
What is the earnings growth outlook for QIAGEN N.V.?
The Earnings per Share (EPS) of QIAGEN N.V. (QGEN) is expected to grow by 7.77% in the next year.